BEGIN:VCALENDAR
VERSION:2.0
PRODID:-//Science in Boston - ECPv6.17.4//NONSGML v1.0//EN
CALSCALE:GREGORIAN
METHOD:PUBLISH
X-WR-CALNAME:Science in Boston
X-ORIGINAL-URL:https://scienceinboston.com
X-WR-CALDESC:Events for Science in Boston
REFRESH-INTERVAL;VALUE=DURATION:PT1H
X-Robots-Tag:noindex
X-PUBLISHED-TTL:PT1H
BEGIN:VTIMEZONE
TZID:America/New_York
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20190310T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20191103T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20200308T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20201101T060000
END:STANDARD
BEGIN:DAYLIGHT
TZOFFSETFROM:-0500
TZOFFSETTO:-0400
TZNAME:EDT
DTSTART:20210314T070000
END:DAYLIGHT
BEGIN:STANDARD
TZOFFSETFROM:-0400
TZOFFSETTO:-0500
TZNAME:EST
DTSTART:20211107T060000
END:STANDARD
END:VTIMEZONE
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T123000
DTEND;TZID=America/New_York:20200122T130000
DTSTAMP:20191209T230217Z
CREATED:20191209T230217Z
LAST-MODIFIED:20191209T230217Z
UID:7519-1579696200-1579698000@scienceinboston.com
SUMMARY:Synthetic Control Arms in Clinical Trials and Regulatory Applications
DESCRIPTION:Overview\n\nAs an increasing number of rare diseases and disease subsets become tractable to novel therapies\, there is growing pressure to increase the efficiency and effectiveness of clinical trials. One such approach is the use of real-world evidence\, such as synthetic control arms. Instead of recruiting patients who have been assigned to the control arm\, a synthetic control arm can repurpose historical clinical trial or real-world data to accurately match patients. This methodology has far-ranging applications in trial design\, replacement/augmentation of control groups and identifying differentiation in treatment effects across subpopulations. \nThis webinar will discuss the methodology and applicability of synthetic control arms\, especially those utilizing large clinical trial datasets\, in biopharma R&D. We will also discuss examples where synthetic controls have successfully been used in FDA applications\, and the emerging regulatory framework.
URL:https://scienceinboston.com/event/synthetic-control-arms-in-clinical-trials-and-regulatory-applications/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T123000
DTEND;TZID=America/New_York:20200122T130000
DTSTAMP:20191209T230217Z
CREATED:20191209T230217Z
LAST-MODIFIED:20191209T230217Z
UID:27417-1579696200-1579698000@scienceinboston.com
SUMMARY:Synthetic Control Arms in Clinical Trials and Regulatory Applications
DESCRIPTION:Overview\n\nAs an increasing number of rare diseases and disease subsets become tractable to novel therapies\, there is growing pressure to increase the efficiency and effectiveness of clinical trials. One such approach is the use of real-world evidence\, such as synthetic control arms. Instead of recruiting patients who have been assigned to the control arm\, a synthetic control arm can repurpose historical clinical trial or real-world data to accurately match patients. This methodology has far-ranging applications in trial design\, replacement/augmentation of control groups and identifying differentiation in treatment effects across subpopulations. \nThis webinar will discuss the methodology and applicability of synthetic control arms\, especially those utilizing large clinical trial datasets\, in biopharma R&D. We will also discuss examples where synthetic controls have successfully been used in FDA applications\, and the emerging regulatory framework.
URL:https://scienceinboston.com/event/synthetic-control-arms-in-clinical-trials-and-regulatory-applications-2/
LOCATION:Online
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T160000
DTEND;TZID=America/New_York:20200122T180000
DTSTAMP:20191209T231059Z
CREATED:20191209T231059Z
LAST-MODIFIED:20191209T231059Z
UID:7521-1579708800-1579716000@scienceinboston.com
SUMMARY:38th Annual JP Morgan Healthcare Conference Recap & 2020 Outlook
DESCRIPTION:The annual JP Morgan Healthcare Conference in San Francisco is one of the largest and most informative healthcare investment symposiums in the industry. It brings together global industry leaders\, emerging fast-growth companies\, innovative technology creators and members of the investment community. Each year hundreds of companies\, both public and private\, deliver presentations to over 4\,000 investors. In addition\, thousands in biotech descend upon San Francisco to network\, attend meetings and gain an inside view even if they can’t secure an official conference invite. If you can’t make it to the conference\, or if your role does not require you to attend the JP Morgan conference\, join us for a recap of it and hear ideas about the deals landscape for 2020 from a select group of conference insiders.
URL:https://scienceinboston.com/event/38th-annual-jp-morgan-healthcare-conference-recap-2020-outlook/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T160000
DTEND;TZID=America/New_York:20200122T180000
DTSTAMP:20191209T231059Z
CREATED:20191209T231059Z
LAST-MODIFIED:20191209T231059Z
UID:27418-1579708800-1579716000@scienceinboston.com
SUMMARY:38th Annual JP Morgan Healthcare Conference Recap & 2020 Outlook
DESCRIPTION:The annual JP Morgan Healthcare Conference in San Francisco is one of the largest and most informative healthcare investment symposiums in the industry. It brings together global industry leaders\, emerging fast-growth companies\, innovative technology creators and members of the investment community. Each year hundreds of companies\, both public and private\, deliver presentations to over 4\,000 investors. In addition\, thousands in biotech descend upon San Francisco to network\, attend meetings and gain an inside view even if they can’t secure an official conference invite. If you can’t make it to the conference\, or if your role does not require you to attend the JP Morgan conference\, join us for a recap of it and hear ideas about the deals landscape for 2020 from a select group of conference insiders.
URL:https://scienceinboston.com/event/38th-annual-jp-morgan-healthcare-conference-recap-2020-outlook-2/
LOCATION:MassBio\, 300 Technology Square 8th Fl\, Cambridge\, MA\, 02139\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T180000
DTEND;TZID=America/New_York:20200122T210000
DTSTAMP:20200102T190923Z
CREATED:20200102T190923Z
LAST-MODIFIED:20200102T190923Z
UID:7657-1579716000-1579726800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:The microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo \n 
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
BEGIN:VEVENT
DTSTART;TZID=America/New_York:20200122T180000
DTEND;TZID=America/New_York:20200122T210000
DTSTAMP:20200102T190923Z
CREATED:20200102T190923Z
LAST-MODIFIED:20200102T190923Z
UID:27421-1579716000-1579726800@scienceinboston.com
SUMMARY:Going Beyond the Gut: The Future of Microbiome Therapeutics
DESCRIPTION:The microbiome market is one of the hottest areas for innovation in the life sciences space.  We are seeing an uptick in both research and venture capital dollars going into the microbiome industry—both in humans and plants.  As a result\, the global microbiome market is expected to grow from $235.8 million in 2018 to $521.23 million by 2022. \nPlease join us for a panel discussion led by some of Boston’s most innovative companies in the space to learn about the science behind the microbiome\, the utilization of emerging technologies\, and various perspectives on the future of the industry. \nConfirmed Speakers \nRyan Barrett\, VP\, Corporate Development & IP\,  Axial Biotherapeutics \nDr. Martha Herbert \, Assistant Professor of Neurology\, Harvard Medical School\, Pediatric Neurologist and Neuroscientist\,  Massachusetts General Hospital \nGeoff van Maltzahn\, Co-founder and Chief Innovation Officer\,  Indigo \n 
URL:https://scienceinboston.com/event/going-beyond-the-gut-the-future-of-microbiome-therapeutics-2-2/
LOCATION:Broad Institute of MIT and Harvard\, 415 Main Street Auditorium\, Cambridge\, MA\, 02142\, United States
END:VEVENT
END:VCALENDAR